News

The formulation will be based on the Company’s proprietary ARCUS technology, and will be produced in collaboration with the Massachusetts Institute of Technology (MIT). RDS is a condition

The sNDS includes data to support: 1) High Dose Bolus administration of Aggrastat; and 2) an indication expansion for the reduction of major cardiovascular events in patients with

The patent claims are directed to the composition of matter and methods of use, including inhibiting tissue damage caused by ultraviolet radiation and promoting neurite outgrowth and neuron

The results were presented at the World Health Organization’s (WHO) fifth teleconference on Ebola vaccine clinical trials. The results showed that the Ebola GP Vaccine was highly immunogenic,

The initial agreement announced in February 2014 focused on the discovery and development of five pre-defined Nanobody candidates directed towards immune checkpoint modulator targets for evaluation as immunotherapies

The approval is based on data from three clinical studies including Phase Ib KEYNOTE-001 trial, Phase II KEYNOTE-002 trial and Phase III KEYNOTE-006 trial conducted in more than

With this expansion, Pfizer has leased the complete 500,000ft² at 610 Main Street in Kendall Square and this space will continue to house the research and development (R&D)

With the in cell factory technology, living cells can be controlled and manipulated to make specific proteins with therapeutic benefits. Under the deal, MedImmune will provide funding and

The Yokebe is expected to generate about €30m in full year 2015 net sales. Yokebe comes in a shake/liquid form and is marketed within the ‘meal replacement’ category.